NAMS

NewAmsterdam Pharma Company N.V. Ordinary Shares

31.59

USD

NAMS Earnings Reports

Positive Surprise Ratio

NAMS beat 5 of 9 last estimates.

56%

Next Report

Date of Next Report

Mar 04, 2026

Estimate for Q4 25 (Revenue/ EPS)

$5.46M

-$0.39

Implied change from Q3 25 (Revenue/ EPS)

+1470.37%

-36.07%

Implied change from Q4 24 (Revenue/ EPS)

-57.21%

-58.06%

NewAmsterdam Pharma Company N.V. Ordinary Shares earnings per share and revenue

On Nov 05, 2025, NAMS reported earnings of -0.61 USD per share (EPS) for Q3 25, missing the estimate of -0.40 USD, resulting in a -50.95% surprise. Revenue reached 348.00 thousand, compared to an expected 5.39 million, with a -93.55% difference. The market reacted with a +4.37% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 16 analysts forecast an EPS of -0.39 USD, with revenue projected to reach 5.46 million USD, implying an decrease of -36.07% EPS, and increase of 1470.37% in Revenue from the last quarter.

FAQ

What were NewAmsterdam Pharma Company N.V. Ordinary Shares's earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, NewAmsterdam Pharma Company N.V. Ordinary Shares reported EPS of -$0.61, missing estimates by -50.95%, and revenue of $348.00K, -93.55% below expectations.

How did the market react to NewAmsterdam Pharma Company N.V. Ordinary Shares's Q3 2025 earnings?

The stock price moved up 4.37%, changed from $36.53 before the earnings release to $38.13 the day after.

When is NewAmsterdam Pharma Company N.V. Ordinary Shares expected to report next?

The next earning report is scheduled for Mar 04, 2026.

What are the forecasts for NewAmsterdam Pharma Company N.V. Ordinary Shares's next earnings report?

Based on 16 analysts, NewAmsterdam Pharma Company N.V. Ordinary Shares is expected to report EPS of -$0.39 and revenue of $5.46M for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.